Dyne Therapeutics Announces U.S. FDA Clearance Of Investigational New Drug (Ind) Application For Dyne-302 In Facioscapulohumeral Muscular Dystrophy (Fshd)
DYN•FDA clears IND for Dyne-302
Dyne Therapeutics, Inc. DYN.O said the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for Dyne-302 in facioscapulohumeral muscular dystrophy (FSHD).
The company said it plans to conduct a Phase 1 placebo-controlled trial for Dyne-302 in FSHD.
